SCNI — Scinai Immunotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.03m
- $14.27m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | 10-K |
Standards: | IFRS | IFRS | IFRS | IFRS | USG |
Status: | fx Final | fx Final | fx Final | fx Final | Final |
Net Income/Starting Line | -24.4 | -30.7 | -1.3 | -12.4 | -5.8 |
Depreciation | |||||
Non-Cash Items | 3.44 | 9.5 | -16.3 | 7.41 | -2.3 |
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 4.99 | -0.942 | -4.25 | -3.36 | 0.271 |
Change in Accounts Receivable | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -15.9 | -21.6 | -21.1 | -7.58 | -7.26 |
Capital Expenditures | -6.61 | -2.09 | -1.78 | -0.133 | -0.836 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0.077 | 0.065 | 0.057 | 0.021 | — |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -6.53 | -2.02 | -1.73 | -0.112 | -0.836 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 23.5 | 23.9 | 3.99 | 21 | 6.78 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.25 | -0.959 | -18.3 | 13.8 | -3.3 |